Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials

Adding PD-1/PD-L1 Inhibitors to Chemotherapy for the First-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC): A Meta-Analysis of Randomized Trials

Survival outcomes in extensive-stage small cell lung cancer (ES SCLC) are dismal, with median overall survival (OS) less than 12 months. The combination of PD-1/PD-L1 immune checkpoint inhibitors (ICIs) with first-line platinum-etoposide chemotherapy has been recently evaluated in randomized clinica...

Full description

Bibliographic Details
Main Authors: Francesco Facchinetti, Massimo Di Maio, Marcello Tiseo
Format: Article
Language:English
Published: MDPI AG 2020-09-01
Series:Cancers
Subjects:
small cell lung cancer (SCLC)
immunotherapy
first-line chemotherapy
meta-analysis
PD-1/PD-L1
Online Access:https://www.mdpi.com/2072-6694/12/9/2645

Internet

https://www.mdpi.com/2072-6694/12/9/2645

Similar Items